Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of PF-08046054/SGN-PDL1V versus docetaxel in previously treated PD-L1-positive NSCLC
MOH_2025-09-11_014337Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing PF-08046054 monotherapy with docetaxel monotherapy (2 arms). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
SGN-PDL1Vdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-09-11_014337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-11_014337.